Truist Securities lowers Astrana Health stock price target to $37 on guidance reset

Investing.comWednesday, November 12, 2025 at 3:29:34 PM
Truist Securities lowers Astrana Health stock price target to $37 on guidance reset
Truist Securities has lowered its stock price target for Astrana Health to $37 following a reset in guidance. This adjustment reflects changes in the company's outlook and is significant for investors as it may influence market perceptions and trading strategies related to Astrana Health. The revision indicates a cautious approach by Truist Securities, highlighting potential challenges or shifts in the company's performance expectations.
— via World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended Readings
Truist Securities raises Alkermes stock price target to $55 on positive trial data
PositiveFinancial Markets
Truist Securities has raised its price target for Alkermes stock to $55 following positive trial data. This adjustment reflects the firm's confidence in the company's future performance based on recent developments in its clinical trials. The new target indicates a bullish outlook for Alkermes in the market.